A sensible acquisition technique has made Bristol-Meyers, which has purchased seven firms since October 2007, a giant participant within the cancer-treatment trade. Its buy of Medarex in July added a key drug for metastic melanoma that’s in Section III trials. The drug has potential a number of indications – trade jargon for its skill to deal with multiple situation – for lung and prostate most cancers.However BMY additionally sells Erbitux for colorectal, head and neck most cancers, Ixempra for breast most cancers, Taxol for brea
